Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30479180 | 1.00 | MAPT (0.46) | MAPTCYP1A2RECQLKDM4EMMP13 | |
| SCHEMBL4286233 | 0.98 | MAPT (0.44) | MAPTCYP1A2RECQLKDM4EMMP13 | |
| SCHEMBL19993836 | 0.79 | DDB1 (0.43) | CYP1A2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL190786 | 0.78 | SLC18A3 (0.51) | MAPTKDM4EMCL1SLC18A3TLR4 | |
| SCHEMBL9328018 | 0.78 | SLC18A3 (0.51) | MAPTKDM4EMCL1SLC18A3TLR4 | |
| SCHEMBL15874652 | 0.78 | SLC18A3 (0.51) | MAPTKDM4EMCL1SLC18A3TLR4 | |
| SCHEMBL9329013 | 0.77 | SLC6A4 (0.42) | CYP1A2SLC6A4 | |
| SCHEMBL15660493 | 0.77 | SLC18A3 (0.50) | MAPTKDM4EMCL1SLC18A3TLR4 | |
| SCHEMBL4063122 | 0.77 | SLC18A3 (0.50) | MAPTKDM4EMCL1SLC18A3TLR4 | |
| Hydrogen Peroxide SCHEMBL14842506 | 0.77 | MCL1 (0.53) | MAPTKDM4EMCL1SLC18A3TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527130-B | Synthesis method of alpha-amide, alpha-aryl quaternary carboketone compound | 兰州大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-113527130-A | Synthetic method of alpha-amide and alpha-aryl quaternary carbon ketone compound | 兰州大学 | 2021-10-22 | — | — | CN | disclosed |
| CN-109232149-B | Synthetic method of alpha-fluoro-alpha-substituted ketone with fluorine-containing quaternary carbon central structure | 兰州大学 | 2021-04-02 | — | — | CN | disclosed |
| EP-3515914-A1 | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | BeiGene, Ltd. (KY) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018054365-A1 | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | BEIGENE, LTD. (KY) | 2018-03-29 | — | — | WO | disclosed |
| CN-106632200-A | Synthesis method of alpha-nitrocycloalkanone | 兰州大学 | 2017-05-10 | — | — | CN | disclosed |
| US-8436005-B2 | Macrocyclic pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2013-05-07 | — | — | US | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| US-7332260-B2 | Naphthopyrans annelated in C5-C6, their preparation and compositions and (CO)polymer matrices containing them | CORNING INCORPORATED (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332260-B2 | Naphthopyrans annelated in C5-C6, their preparation and compositions and (CO)polymer matrices containing them | CORNING INCORPORATED (US) | 2008-02-19 | — | — | US | disclosed |
| US-4187152-A | Extractive distillation for separating ketones and/or alcohols from phenol and/or cresol | ALLIED CHEMICAL CORPORATION (US) | 1980-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | MAPT 2013/4885CYP1A2 1655/4885RECQL 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.